|
||||
 |
||||
Dockets
Management
|
||||
|
Food and Drug Administration Anti-Infective Drugs Advisory CommitteeNovember 19, 2008
BREIFING INFORMATION
Morning Session
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).
FDA Briefing Material (pdf)
Theravance, Inc
Disclaimer
The statements contained in this document(s) are those of
the product's sponsor, not FDA, and FDA does not necessarily agree with the
sponsor's statements. FDA has not made a final determination about the safety
or effectiveness of the product described in this document.
Theravance Briefing Material (pdf)
Afternoon
Session
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §
552).
FDA Briefing Material (pdf)
Targanta
Therapeutics Corporation
Disclaimer
The statements contained in this document(s) are those of
the product's sponsor, not FDA, and FDA does not necessarily agree with the
sponsor's statements. FDA has not made a final determination about the safety
or effectiveness of the product described in this document.
Targanta Therapeutics Briefing Material (pdf)
Page last updated
November 14, 2008
kk |
